Drug Profile

LYG LIV 0001

Alternative Names: LYG-LIV-0001; LYG-LIV-001

Latest Information Update: 14 Jan 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Pittsburgh
Developer LyGenesis
Class Cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Liver failure

Most Recent Events

23 Dec 2021 Phase-II clinical trials in Liver failure in USA (Parenteral) (NCT04496479)
30 Dec 2020 LyGenesis plans a phase II trial for Liver Failure in early 2021 (NCT04496479)
30 Dec 2020 LyGenesis receives clearance from US FDA for LYG LIV 0001 in Liver failure

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com